K K Pai National Banking Award' for K V Kamath

Bengaluru, Jul 6: A video clip of a Bengaluru-based doctor urging the follow doctors to return to their duty at a time when medicos are desperately needed to fight against COVID-19 has busted the myth of ‘shortage of beds’ in the hospitals. 

In past few of weeks, dozens of people in Bengaluru have lost their lives after hospital denied them admission citing lack of beds. 

Dr Taha Mateen, Managing Director of HBS Hospital, in an emotional message, appealed to healthcare professionals, including doctors, to help handle the situation better. The video has gone viral on social media.

“I speak from the ICU of HBS Hospital. It’s been a virtual bloodbath. I came in the morning at like 7:30 in the morning and its 12’o’clock midnight right now. Patients are continuously calling me now ‘cause their fathers are breathless, their brothers are breathless and they cannot find a room in Bengaluru and at this time if you see there is one Mr Shiva and me. There is no other doctor willing to work in this hospital,” Dr Mateen says in the video.

Dr Mateen further said, "I have beds, I have oxygen beds, I have ventilators, I have all the equipment. I have another 30 beds like this but I don’t have doctors working here.” He said that there is an urgent need to mobilise healthcare staff.

Sources said the COVID-19 patients at the hospital are left with only five doctors and 12 nurses. Until recently, the HBS Hospital had 20 nurses and 44 doctors on its roll.

According to a report, the hospital is facing huge difficulties in treating patients admitted at Intensive Care Units (ICU). Eight patients with severe respiratory problems are admitted to the hospital and are waiting for their COVID-19 test results.

"We have sufficient beds at the hospital to treat coronavirus patients, but we don't have doctors. And we can't admit more patients as we are left with just five doctors, said Dr Taha Mateen.

"All doctors are on WhatsApp, I request all doctors to come out and perform their duties, Dr Mateen said in a video appeal on WhatsApp, Twitter and Instagram. 

According to Dr Mateen, a COVID-19 patient, who was admitted to COVID care centre at Haj  Bhavan, was abandoned on a road by an ambulance driver. Later, the patient was picked by NGO volunteers. 

"The patient was brought to HBS Hospital at 2 am. He had a very low blood oxygen level. We stabilised his condition. Later, we had to send him home as we don't have enough staff to take care of him. We also sent an oxygen cylinder to his home," a report quoted Dr Mateen as saying.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.